Evolus EOLS 深 沪
已收盘 12-19 16:00:00 美东时间
7.07
-0.110
-1.53%
华盛通- 最 高7.17
- 今 开7.11
- 成交量 168.79万股
- 最 低 7.005
- 昨 收 7.18
- 总市值 4.57亿
- 52周最高 17.12
- 市盈率 静 --
- 换手率 2.61%
- 52周最低 5.71
- 委 比 -58.50%
- 总股本 6468.54万
- 历史最高 39.50
- 量 比 2.38
- 振 幅 2.30%
- 历史最低 2.85
- 每 手 1
- 风险率 2.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma granted 392,158 restricted stock units (RSUs) to newly hired non-executive employees in December 2025, vesting over four years under its 2025 Inducement Incentive Plan. The company is focused on developing ABP-450, a biosimilar to BOTOX, targeting the $3 billion U.S. therapeutic neurotoxin market. ABP-450 is approved as a biosimilar in India, Mexico, and the Philippines and is being developed under the FDA's biosimilar pathway, whi...
12-19 23:00
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
<p>AEON Biopharma与Daewoong Pharmaceutical达成协议，将1500万美元的可转换债券加上累计利息转换为新股、150万美元的2030年到期新债券及800万股普通股的现金行使认股权证。该交易需股东审批，AEON CEO Rob Bancroft表示这是去杠杆化的重要步骤，并为2026年的ABP-450生物类似药策略铺路。该交易将减少AEON超过90%的债务，加强Daewoong的长期战略合作，并改善AEON的资本结构。</p>
12-15 21:05
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
Mizuho Maintains Outperform on Evolus, Lowers Price Target to $19
Mizuho analyst Uy Ear maintains Evolus (NASDAQ:EOLS) with a Outperform and lowers the price target from $20 to $19.
12-02 23:29
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
AEON Biopharma announced positive biosimilarity data for ABP-450, a BOTOX biosimilar, confirming identical amino-acid sequencing and highly similar functional characteristics. The company submitted these results to the FDA ahead of a scheduled Type 2a meeting on November 19, 2025. Additionally, AEON completed two financing transactions in November 2025—a $6 million PIPE financing and a proposed Daewoong note exchange—which are expected to reduce ...
11-14 13:30
Evolus, Inc. Earnings Call Highlights Growth and Resilience
Evolus, Inc. (($EOLS)) has held its Q3 earnings call. Read on for the main high...
11-11 08:13
CORRECTION: Evolus Q3 Adj. EPS $(0.11) Beats $(0.17) Estimate, Sales $68.967M Beat $67.449M Estimate
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 36.05 percent. This is a 35.29 percent increase over losses of $(0.17) per share from the same
11-06 07:42
Evolus shares are trading higher after the company reported better-than-expected Q3 financial results.
Evolus shares are trading higher after the company reported better-than-expecte...
11-06 05:25
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
BTIG Reiterates Buy on Evolus, Maintains $18 Price Target
BTIG analyst Sam Eiber reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $18 price target.
09-08 23:49
